Amgen at ENA 2026

Nov 18–20, 2026 Barcelona, Spain ~1.5k attendees Website

Amgen brings 2 presentations to ENA 2026 in Barcelona. Its program spans the interface between GLP-1 drugs and cancer and the discovery of a first-in-class MTA-cooperative PRMT5 inhibitor. The PRMT5 work describes how that inhibitor was identified and optimized.

OrganizationENA 2026 Attendance
Amgen
Thousand Oaks, CA
Large pharma
Global biotechnology drugmaker with oncology medicines including bispecific T-cell engagers and the KRAS G12C inhibitor sotorasib.
Session
Wed Nov 18
4:15–5:45pm

Explore the full ENA 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Barcelona. Leave your work email and we’ll be in touch.

Privacy

Download the full ENA 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Amgen

Tell us what you sell and we’ll find the people at Amgen most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by EORTC, the NCI or the AACR. Submit a correction